Evotec (NASDAQ:EVO) Hits New 52-Week Low – Should You Sell?

Evotec AG (NASDAQ:EVO) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $1.86 and last traded at $1.87, with a volume of 10644 shares traded. The stock had previously closed at $1.91.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on EVO shares. HC Wainwright decreased their price target on Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, July 15th. Weiss Ratings lowered shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.00.

Evotec Stock Performance

The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. The business’s fifty day simple moving average is $2.23 and its 200-day simple moving average is $2.68.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its stake in Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after acquiring an additional 367,545 shares during the last quarter. WCM Investment Management LLC boosted its position in Evotec by 12.1% in the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after buying an additional 67,917 shares during the period. ABC Arbitrage SA grew its stake in Evotec by 319.7% in the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after acquiring an additional 422,230 shares in the last quarter. Optiver Holding B.V. grew its stake in Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after acquiring an additional 242,973 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Evotec in the 4th quarter worth about $565,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.